Valneva SE
Valneva SE (INRLF) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · INRLF · as of Jun 9, 2026
Key Statistics
Explore Valneva SE Data
inrlf stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 1 · Buy rate: 100.0%
Competitors & Peers
inrlf competitorsINRLF
AVCTF
BPMUF
ELEAF
GSGTF
IDRSFStock Performance
Full HistoryAbout Valneva SE
Valneva SE operates as a specialized biopharmaceutical entity, primarily focused on the creation and commercialization of preventative vaccines for infectious diseases where effective treatments are c…
what is valneva se · inrlf stock overview · valneva se company profile · who is valneva se ceo · inrlf OTC · valneva se headquarters · valneva se business segments
About Stock Overview & Key Data
Valneva SE (INRLF) is a Healthcare company in the Biotechnology industry, listed on OTC since Apr 23, 2010. As of the latest trading session, INRLF stock price is $2.80, with a market capitalization of $531.0M. The stock has returned -13.85% over the past 12 months and -33.33% year-to-date.
According to 1 Wall Street analysts, the consensus rating for Valneva SE stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, Valneva SE reported revenue of $174.7M and net income of -$115.2M. For detailed data — including Valneva SE revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Valneva SE (INRLF) stock price is $2.80. The stock is traded on OTC under the ticker symbol INRLF. The 52-week range is $2.46 – $6.28.